David L. Veenstra, PharmD, PhD

This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted next-generation sequencing (NGS) panels.

Periodic reinterpretation of genetic sequencing results presents a challenge for developing transparent and systematic coverage and reimbursement policies.

This study critically assessed the published clinical and economic evidence supporting oncology orphan drugs marketed in the United States.